RA Capital Management

Founded 2001
Founders Richard Aldrich


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 203
Average round size
The average size of a deal this fund participated in
Portfolio companies 195
Rounds per year 10.15
Lead investments 29
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 100
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical

RA Capital Management appeared to be the VC, which was created in 2001. The leading representative office of defined VC is situated in the Boston. The venture was found in North America in United States.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the RA Capital Management, startups are often financed by OrbiMed, F-Prime Capital, Flybridge Capital Partners. The meaningful sponsors for the fund in investment in the same round are Wellington Management, Longitude Capital, Deerfield. In the next rounds fund is usually obtained by OrbiMed, Cormorant Asset Management, Polaris Partners.

Opposing the other organizations, this RA Capital Management works on 23 percentage points more the average amount of lead investments. The fund is generally included in 7-12 deals every year. The real fund results show that this VC is 4 percentage points more often commits exit comparing to other companies. The average startup value when the investment from RA Capital Management is more than 1 billion dollars. The increased amount of exits for fund were in 2015. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 50 - 100 millions dollars.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline AveXis, Moderna Therapeutics, Intarcia Therapeutics Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Health Care, Health Diagnostics.

This organization was formed by Richard Aldrich. We also calculated 4 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of RA Capital Management:
Typical Co-investors
RA Capital Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after RA Capital Management:

Funds with similar focus

Funds from United States, Boston
Funds with similar focus located in United States, Boston:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Asher Bio

$108M01 Sep 2021 United States, San Francisco

ARS Pharmaceuticals

Health Care
$55M31 Aug 2021 United States, San Diego


Health Care
$50M18 Aug 2021 United States, Boston


Life Science
$157M11 Aug 2021 United States, Seattle


$45M10 Aug 2021 United States, " United States"}


Clinical Trials
$112M05 Aug 2021 United Kingdom, Oxford


$110M02 Aug 2021 Germany, Berlin


Health Care
26 Jul 2021 United States, Lynchburg


Life Science
$55M22 Jul 2021 Denmark, Copenhagen
Obsidian Therapeutics Closes $115M Series B Financing
– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies. – The company closed a $115m Series B financing. – The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Am... Read more
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures. – The pro... Read more


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent RA Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: